Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1366570 | 0.88 | PARP1 (0.38) | PTGS1PTGS2TSHRTBXAS1 | |
| SCHEMBL1369142 | 0.85 | KDR (0.47) | — | |
| SCHEMBL1369203 | 0.79 | RAB9A (0.51) | TSHRNPC1RAB9A | |
| SCHEMBL1369731 | 0.78 | HSPA5 (0.39) | L3MBTL1PTGS1PTGS2POLB | |
| SCHEMBL1369743 | 0.78 | PTGDR2 (0.48) | — | |
| SCHEMBL14999786 | 0.76 | CYP2C9 (0.42) | TSHR | |
| SCHEMBL1370028 | 0.76 | SRD5A2 (0.40) | L3MBTL1PTGS1PTGS2TSHRRAB9A | |
| SCHEMBL1369034 | 0.76 | PTGDR2 (0.52) | NPC1RAB9APOLB | |
| SCHEMBL1369033 | 0.75 | PTGS1 (0.44) | PTGS1PTGS2 | |
| SCHEMBL2486672 | 0.75 | AR (0.49) | L3MBTL1PTGS1PTGS2TSHRPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2011-11-24 | — | — | US | disclosed |
| EP-2377851-A1 | ISOQUINOLINE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2011-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288293-A1 | ISOQUINOLINE DERIVATIVE | HRH1, HRH2, HRH4 | L3MBTL1 4825/4885CPB2 3157/4885PTGS1 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.